Plozasiran for Severe Hypertriglyceridemia

Name: Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC
Uploaded: 2026-09-02T04:00:00+00:00
Duration: 3 min 15 s
Description: From ESC 2026 in Munich, Dr. Gerald Watts explores the 12-month findings from the phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in patients with sever

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Dr. Robert Giugliano
- Dr. Robert Giugliano
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Cardiology
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Javier Morales, MD, FACP, FACE
- Javier Morales, MD, FACP, FACE
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
- Nicholas Marston, MD
Evolocumab on top of optimal therapy: effect on carotid plaque
Evolocumab on top of optimal therapy: effect on carotid plaque
ESC Congress 2025
Evolocumab on top of optimal therapy: effect on carotid plaque
Tiziana Claudia Aranzulla, MD
- Tiziana Claudia Aranzulla, MD

Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC

Recommended

Title